Cyclerion Therapeutics Inc.

2.8500.00Vol 202.09K1Y Perf 2.91%
Apr 9th, 2021 16:00 DELAYED
BID2.88 ASK2.89
Open2.85 Previous Close2.85
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     45.37
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap97.06M 
Earnings Rating
Price Range Ratio 52W %
9.88 
Earnings Date
3rd May 2021

Today's Price Range

2.732.88

52W Range

2.188.96

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-13.37%
1 Month
-31.65%
3 Months
-12.58%
6 Months
-57.72%
1 Year
2.91%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CYCN2.850.00000.00
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.59-
Q02 2020--0.70-
Q01 2020--0.73-
Q04 2019--0.95-
Q03 2019--1.00-
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date3rd May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume202.09K
Shares Outstanding34.06M
Trades Count1.27K
Dollar Volume1.52M
Avg. Volume667.19K
Avg. Weekly Volume196.80K
Avg. Monthly Volume301.12K
Avg. Quarterly Volume707.08K

Cyclerion Therapeutics Inc. (NASDAQ: CYCN) stock closed at 2.85 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 249.50K shares and market capitalization of 97.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 34 people. Cyclerion Therapeutics Inc. CEO is Peter M. Hecht.

The one-year performance of Cyclerion Therapeutics Inc. stock is 2.91%, while year-to-date (YTD) performance is -6.86%. CYCN stock has a five-year performance of %. Its 52-week range is between 2.18 and 8.96, which gives CYCN stock a 52-week price range ratio of 9.88%

Cyclerion Therapeutics Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.60, a price-to-sale (PS) ratio of 78.63, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -51.55%, a ROC of -54.34% and a ROE of -98.97%. The company’s profit margin is -%, its EBITDA margin is -2 409.90%, and its revenue ttm is $1.28 Million , which makes it $0.04 revenue per share.

Of the last four earnings reports from Cyclerion Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclerion Therapeutics Inc.’s next earnings report date is 03rd May 2021.

The consensus rating of Wall Street analysts for Cyclerion Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cyclerion Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclerion Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cyclerion Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.92, ATR14 : 0.44, CCI20 : -42.98, Chaikin Money Flow : -0.08, MACD : 0.01, Money Flow Index : 31.12, ROC : -0.99, RSI : 51.29, STOCH (14,3) : 55.56, STOCH RSI : 0.85, UO : 52.20, Williams %R : -44.44), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclerion Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

CEO: Peter M. Hecht

Telephone: +1 857 327-8778

Address: 301 Binney Street, Cambridge 02142, MA, US

Number of employees: 34

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

54%46%

News

Stocktwits